AR062176A1 - Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular - Google Patents

Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular

Info

Publication number
AR062176A1
AR062176A1 ARP070103397A ARP070103397A AR062176A1 AR 062176 A1 AR062176 A1 AR 062176A1 AR P070103397 A ARP070103397 A AR P070103397A AR P070103397 A ARP070103397 A AR P070103397A AR 062176 A1 AR062176 A1 AR 062176A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
hydrogen
alkyl
aminocarbonyl
acyl
Prior art date
Application number
ARP070103397A
Other languages
English (en)
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AR062176A1 publication Critical patent/AR062176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Derivados de nicotinamida que regulan miosina de musculo liso y/o miosina no muscular, y entidades químicas, composiciones farmacéuticas y su uso en el tratamiento de enfermedades y condiciones asociadas con miosina de musculo liso y/o miosina no muscular. Reivindicacion 1: Al menos una entidad química seleccionada de compuestos de la Formula (X) y sus sales farmacéuticamente aceptables, en donde W1 se elige de N y CR6 y W2 se elige de N y CR4, siempre que ambos W1 y W2 no son N; R1 y R4 independientemente se eligen de hidrogeno, ciano, halo, hidroxi, azido, nitro, sulfonilo, sulfinilo, sulfanilo, alcoxi opcionalmente sustituido, aciloxi opcionalmente sustituido, aminocarboniloxi opcionalmente sustituido, ariloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heterocicloalquiloxi opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, ariloxi opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, amino opcionalmente sustituido, acilo opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, y carbaminodoilo opcionalmente sustituido; Z1 se elige de hidrogeno, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, ciano, alquilo opcionalmente sustituido, acilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, amino opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, carbamimidoilo opcionalmente sustituido, alcoxi opcionalmente sustituido, ariloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heterocicloalquiloxi opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, sulfonilo, sulfinilo, y sulfanilo; Z2 se elige de hidrogeno, amidino opcionalmente sustituido, carboxilo, alcoxicarbonilo opcionalmente sustituido, acilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, y aminocarbonilo opcionalmente sustituido; Z3 se elige de hidrogeno, halogeno, y alquilo opcionalmente sustituido; R3 se elige de hidrogeno y alquilo opcionalmente sustituido; y R6 se elige de hidrogeno, acilo opcionalmente sustituido, alquilo opcionalmente sustituido, ciano, halo, azido, amino opcionalmente sustituido, aloxicarbonilo opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, sulfonilo, sulfinilo, y sulfanilo.
ARP070103397A 2006-08-01 2007-08-01 Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular AR062176A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83490106P 2006-08-01 2006-08-01
US83490406P 2006-08-01 2006-08-01
US83518306P 2006-08-01 2006-08-01
US83501006P 2006-08-01 2006-08-01
US83490306P 2006-08-01 2006-08-01
US83523606P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
AR062176A1 true AR062176A1 (es) 2008-10-22

Family

ID=38997696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103397A AR062176A1 (es) 2006-08-01 2007-08-01 Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular

Country Status (4)

Country Link
AR (1) AR062176A1 (es)
PE (1) PE20080432A1 (es)
TW (1) TW200823188A (es)
WO (1) WO2008016643A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
HUE043536T2 (hu) * 2009-10-06 2019-08-28 Millennium Pharm Inc PDK1 inhibitorként alkalmazható heterociklusos vegyületek
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2015010832A1 (en) * 2013-07-22 2015-01-29 Syngenta Participations Ag Microbiocidal heterocyclic derivatives
JP2017214290A (ja) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze
TW202136268A (zh) 2018-07-13 2021-10-01 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
US20230023124A1 (en) * 2019-11-06 2023-01-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
JP2007533740A (ja) * 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤としてのアミド

Also Published As

Publication number Publication date
TW200823188A (en) 2008-06-01
WO2008016643A3 (en) 2008-06-19
WO2008016643A2 (en) 2008-02-07
PE20080432A1 (es) 2008-05-29

Similar Documents

Publication Publication Date Title
AR062176A1 (es) Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
UY29246A1 (es) Nuevos compuestos
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
DK1996180T3 (da) Benzamid- og pyridylamidderivater som antibakterielle midler
NO20090628L (no) Pyridizinon derivativater
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
UY29875A1 (es) Compuestos quimicos
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
AR069364A1 (es) Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen
ATE384058T1 (de) Thiazolderivate
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
SE0403171D0 (sv) New compounds
DK1781299T3 (da) Anti-inflammatoriske midler
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.

Legal Events

Date Code Title Description
FB Suspension of granting procedure